Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Massive study seeks safer chemo recovery for thousands

NCT ID NCT07409415

Knowledge-focused Sponsor: Huazhong University of Science and Technology Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 3000 cancer patients to see which treatments work best for preventing dangerously low white blood cell counts after chemotherapy. It compared different approaches to see how well they prevent infections and improve quality of life. The goal is to give doctors real-world evidence to choose the best strategy for each patient.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

3,000 people

The number who actually took part.

Started

Feb 2024

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Breast cancer, lung cancer, colorectal cancer, gynecological cancers, esophageal cancer, head and neck cancers, and other non-myeloid malignant tumors.

Ages

14 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients diagnosed with non-myeloid malignant tumors (such as breast cancer, lung cancer, colorectal cancer, gynecological cancers, esophageal cancer, head and neck cancers) through imaging, histopathological examination, etc. 2. Patients who have received at least two cycles of chemotherapy. 3. Patients with a white blood cell (WBC) count \> 3.0 × 10⁹/L or an absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L before chemotherapy. 4. Patients with osteosarcoma or lymphoid leukemia must be ≥ 14 years of age; patients with other cancer types must be ≥ 18 years of age. 5. Patients who voluntarily agree to participate in this study. 6. Patients who do not develop serious complications after chemotherapy. Exclusion Criteria: 1. Patients with psychiatric disorders. 2. Patients with language or communication barriers. 3. Patients with severe dysfunction of the liver, kidneys, heart, or lungs. 4. Patients with severe bone marrow suppression. 5. Patients who have received systemic bone radiotherapy within 15 days. 6. Patients who have experienced a significant infection within the two weeks prior to study entry.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer colorectal cancer esophageal cancer female reproductive organ cancer head and neck cancer lung cancer lymphoid leukemia osteosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-myeloid malignant tumors

Contacts and locations

Locations

  • Tongji hospital of Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.